INSIGHTS ON SOLID DOSE MANUFACTURING

• From Powder To Robust Tablet With Less Material: Compaction Simulator Arrives At Ardena Ghent

  Advanced compaction simulation predicts formulation performance and tablet strength with minimal material, streamlining scale-up and accelerating development to clinical manufacturing.

• Zhunan Facility Site VR Tour

  Bora’s 36,000-square-meter Zhunan, Taiwan facility delivers flexible, high-quality cGMP oral solid dose manufacturing with access to major markets including North America and the EU.

• A Simple And Powerful Solution For Accelerating Dissolution

  Many poorly soluble drugs fail not because of low solubility, but because they dissolve too slowly. Learn how focusing on dissolution rate can unlock absorption gains using simple strategies.

• GLP-1 OSD Chemical Synthesis Workflow

  Enhance containment and process reliability in oral GLP-1 synthesis. Discover how integrated single-use assemblies and automated fluidics safeguard chemical purity during scale-up.

• Morpho Shreveport Facility: Tablet, Capsule And Packaging Manufacturing Capabilities

  10/13/2026

  Food and supplement manufacturing in Louisiana spans blending, compression, film coating, encapsulation, and several packaging formats, backed by dedicated quality control testing from raw materials through finished product.

• Solubility Enhancement Via Amorphous Solid Dispersions

  2/27/2025

  Polyvinyl alcohol (PVA) is a versatile polymer platform used to enhance solubility through hot melt extrusion. Explore the role it plays in drug solubility, hydrolysis, and thermal behaviors.

• Developing And Manufacturing Drugs With HPAPIs

  1/27/2025

  Learn why companies must invest in specialized expertise to develop scalable, safe, and efficient manufacturing processes for highly potent oral solid dose products.

• Rational Design And Material-sparing Strategies For Enabled Intermediates And Drug Products

  9/9/2026

  A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.

• Safety First: Considerations When Formulating High Potency Compounds

  9/23/2026

  Developing highly potent APIs comes with unique challenges. Explore strategies for managing risk, protecting personnel, and advancing programs with confidence.